Characteristic | LRFS | OS | ||
---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | |
Age (y) | ||||
≤ 35 vs. > 35 | 1.664 (1.082-2.558) | 0.020* | — | |
Menopausal status | ||||
Pre- vs. postmenopausal | 1.623 (1.106-2.383) | 0.105 | — | |
Tumor size | ||||
T3-4 vs. T1-2 | 1.636 (1.029-2.600) | 0.037 | 1.392 (0.917-2.113) | 0.121 |
ER status | ||||
Negative vs. positive | 1.536 (1.095-2.155) | 0.013* | 1.054 (0.699-1.590) | 0.802 |
PR status | ||||
Negative vs. positive | 1.626 (1.148-2.302) | 0.317 | 1.490 (1.040-2.136) | 0.030* |
HER-2-neu status | ||||
Positive vs. negative | — | 1.208 (0.888-1.644) | 0.228 | |
Hormone therapy | ||||
None vs. yes | 1.180 (0.731-1.904) | 0.498 | 1.570(1.093-2.255) | 0.015* |
Lymph node ratio | ||||
< 0.20 | 1 (Reference) | 1 (Reference) | ||
0.21-0.65 | 1.886 (1.273-2.794) | 0.002* | 1.964 (1.387-2.782) | <0.001* |
> 0.65 | 5.013 (3.191-7.877) | <0.001* | 7.381 (5.161-10.557) | <0.001* |
Number of positive lymph nodes | ||||
pN1 | 1 (Reference) | |||
pN2 | 0.828 (0.476-1.442) | 0.522 | 1.327 (0.808-2.179) | 0.263 |
pN3 | 0.894 (0.437-1.828) | 0.907 | 1.654 (0.904-3.027) | 0.103 |